At 29 days, the estimated cumulative rate of clinical resolution was 83% in tecovirimat recipients and 84% in those given placebo.
The test the US Centers for Disease Control and Prevention uses to identify clade I mpox cases is 'most likely not reliable' for detection of the substrain identified in the study, the authors say.
Another mpox study today showed that dose-sparing vaccine administration of the Jynneos vaccine appeared to have worked.
Receive the latest infectious disease information.
So far this year African nations have reported 1,400 monkeypox cases, including 66 deaths.
Also, HHS has asked Bavarian Nordic to deliver 36,000 more vaccine doses this week to the national stockpile.
Cases in nonendemic countries continue to climb, with more than 780 reported in the past 3 weeks.
Also, an expert weighs in on crafting clear public health messaging that doesn't stigmatize yet doesn't miss key groups.
Also, a study notes potential undetected spread of the disease in Europe at least since early April.
"There may have been undetected transmission for a while," a WHO official says.
"There's a window of opportunity where this can be contained," a WHO official says.
More than 20 countries have logged a combined total of more than 300 monkeypox cases.
"The risk of exposure is not limited to any one particular group," CDC director says, adding that the disease doesn't care about borders.
Though given to only 1 patient, tecovirimat was tied to a shorter illness and signs of shorter viral shedding.
